Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

NeoADAURA

The Site Factor - printed report

Where it all began: why we wrote ‘The Site Factor’

Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.

Cuttsy + Cuttsy

- PMLiVE

Gilead to acquire Tubulis for up to $5bn

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

- PMLiVE

Pistoia Alliance publishes first best-practice framework for ethical social media use in drug development

This marks the Alliance's first direct engagement with oncology, rare disease and cardiology patients

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

Marking World Health Day on 7 April

From ‘early-signal’ health to lived outcomes: VML Health unveils the new trends set to define health communications

- PMLiVE

PharmaQuest returns: EPA perspectives, through a rare disease lens

By Lottie Sequerra and Emily Morton-West

Amiculum

- PMLiVE

NEW WEBINAR: Maximizing Speed-to-Outcome for Life Science Companies

Stop losing momentum to the "logistics lag." The most successful life science teams have moved beyond fragmented spreadsheets and isolated meetings into a unified orchestration engine. Learn the strategies that...

Impetus Digital

- PMLiVE

Roche opens new Swiss Institute of Human Biology research facility

The new building is part of a 1.5bn euro site investment

- PMLiVE

ReproNovo appoints Mark Altmeyer as Chairman of the Board

Altmeyer previously held senior roles at Arvelle Therapeutics, Axovant, Bristol Myers Squibb and Otsuka

- PMLiVE

Insight gaps leave Biopharma vulnerable to patent cliff crisis, warns expert

With unprecedented patent cliffs looming, putting an estimated $200 to $400 billion in annual global sales at risk , senior strategy consultant and Nmblr founder, Janice MacLennan, is issuing a...

Nmblr

- PMLiVE

Novartis to acquire Excellergy in deal worth up to $2bn

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

- PMLiVE

Poolbeg Pharma appoints Adrian Kilcoyne to Scientific Advisory Board

Kilcoyne previously held senior roles at AstraZeneca, Celgene, Sanofi, Roche and Eli Lilly

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links